Published in Blood Weekly, September 30th, 1996
Although gene therapy for HIV is still in its infancy, several strategies that target the viral replication cycle via the binding of the regulatory proteins Tat and Rev have been explored. Researchers M. Gottfredsson et al. from Duke University presented data at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, held September 15-18, 1996, in New Orleans, Louisiana, which showed that production of HIV-1 in primary human T cells can be suppressed using a retrovirus-mediated gene therapy protocol...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.